NasdaqGS:MRNA

Stock Analysis Report

Executive Summary

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

Snowflake

Fundamentals

Flawless balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has Moderna's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.07%

MRNA

3.8%

US Biotechs

2.3%

US Market


1 Year Return

n/a

MRNA

-10.0%

US Biotechs

5.6%

US Market

Return vs Industry: Insufficient data to determine how MRNA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how MRNA performed against the US Market.


Shareholder returns

MRNAIndustryMarket
7 Day-0.07%3.8%2.3%
30 Day-19.9%-2.8%-1.0%
90 Day0.3%-2.6%-0.7%
1 Yearn/a-9.2%-10.0%7.9%5.6%
3 Yearn/a14.7%10.7%45.6%36.3%
5 Yearn/a2.2%-2.8%65.8%47.6%

Price Volatility Vs. Market

How volatile is Moderna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moderna undervalued compared to its fair value and its price relative to the market?

3.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate MRNA's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MRNA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MRNA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MRNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MRNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MRNA is overvalued based on its PB Ratio (3.5x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Moderna forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-4.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRNA's revenue (11.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MRNA's revenue (11.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: MRNA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Moderna performed over the past 5 years?

-78.7%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MRNA is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare MRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: MRNA has a negative Return on Equity (-36.57%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MRNA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MRNA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Moderna's financial position?


Financial Position Analysis

Short Term Liabilities: MRNA's short term assets ($1.1B) exceeds its short term liabilities ($162.0M)

Long Term Liabilities: MRNA's short term assets (1.1B) exceeds its long term liabilities (184.7M)


Debt to Equity History and Analysis

Debt Level: MRNA is debt free.

Reducing Debt: MRNA had no debt 5 years ago.


Balance Sheet

Inventory Level: MRNA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MRNA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MRNA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MRNA has sufficient cash runway for 1.818566 years if free cash flow continues to reduce at historical rates of -47.1% each year.


Next Steps

Dividend

What is Moderna's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MRNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Moderna's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Stéphane Bancel (46yo)

8yrs

Tenure

US$58,608,484

Compensation

Mr. Stéphane Bancel serves as Interim President of Valera LLC. Mr. Bancel is Venture Partner of Flagship Pioneering and a Trustee of the Museum of Science in Boston. Mr. Bancel provides strategic counsel a ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Stéphane's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Stéphane's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.0yrs

Average Tenure

50yo

Average Age

Experienced Management: MRNA's management team is considered experienced (3 years average tenure).


Board Age and Tenure

6.5yrs

Average Tenure

58yo

Average Age

Experienced Board: MRNA's board of directors are considered experienced (6.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Noubar Afeyan (56yo)

    Co-Founder

    • Tenure: 7.7yrs
    • Compensation: US$429.75k
  • Lori Henderson (57yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.5yrs
  • John Reynders

    Chief Information Officer

    • Tenure: 6.3yrs
  • Lorence Kim (45yo)

    Chief Financial Officer

    • Tenure: 5.5yrs
    • Compensation: US$9.04m
  • Stéphane Bancel (46yo)

    CEO & Director

    • Tenure: 8yrs
    • Compensation: US$58.61m
  • Juan Andres (54yo)

    Chief Technical Operations & Quality Officer

    • Tenure: 2.2yrs
  • Stephen Hoge (43yo)

    President

    • Tenure: 0yrs
    • Compensation: US$23.95m
  • Lavina Talukdar

    Head of Investor Relations

    • Tenure: 0.5yrs
  • Melissa Moore

    Chief Scientific Officer

    • Tenure: 3yrs
  • Jennifer Lee

    Chief Accounting Officer

    • Tenure: 0yrs

Board Members

  • Noubar Afeyan (56yo)

    Co-Founder

    • Tenure: 7.7yrs
    • Compensation: US$429.75k
  • Peter Hutt (84yo)

    Director

    • Tenure: 7.6yrs
    • Compensation: US$387.14k
  • Bob Langer (70yo)

    Director & Member of Scientific Advisory Board

    • Tenure: 8.8yrs
    • Compensation: US$408.03k
  • Betsy Nabel (67yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$388.75k
  • Stéphane Bancel (46yo)

    CEO & Director

    • Tenure: 8yrs
    • Compensation: US$58.61m
  • Ulrich von Andrian-Werburg

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jack Szostak

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • John Aunins (58yo)

    Member of Technology Advisory Board

    • Tenure: 5.4yrs
  • Israel Ruiz (47yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: US$405.98k
  • Stephen Berenson (58yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$403.48k

Company Information

Moderna, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moderna, Inc.
  • Ticker: MRNA
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.672b
  • Shares outstanding: 330.18m
  • Website: https://www.modernatx.com

Number of Employees


Location

  • Moderna, Inc.
  • 200 Technology Square
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRNANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2018
0QFMUN (Boerse Muenchen)YesCommon StockDEEURDec 2018
0QFDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2018
MRNA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNDec 2018

Biography

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:43
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.